Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Obesity Pillars · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles